博纳西亚冲刺港股IPO：贸易应收款周转天数激增102% 关联方借款高达8970万元存风险

Core Viewpoint - The company, Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd., is a clinical research organization (CRO) that provides clinical trial-related services primarily to pharmaceutical and biotechnology companies. The company has two main business segments: clinical research technical services and functional service provider (FSP) services. In 2023, clinical research technical services generated revenue of 318 million yuan, accounting for 85.7% of total revenue, while FSP services contributed 50.62 million yuan, representing 13.7% of total revenue [1]. Business Model and Revenue Structure - The company operates under two main charging models: Full-Time Equivalent (FTE) model and Fee-for-Service (FFS) model. Under the FTE model, the company provides dedicated teams for client projects at a fixed rate per person, while the FFS model charges based on completed service content. As of September 30, 2025, the company has developed 85 clinical research-related software copyrights, creating a certain level of technical barrier [1]. - The company's revenue has shown a trend of decline followed by recovery. In 2023, revenue was 371 million yuan, which decreased by 8.2% to 340.25 million yuan in 2024, but rebounded to 245.01 million yuan in the first nine months of 2025, reflecting a year-on-year growth of 3.5% [2]. Profitability Metrics - The company's net profit has fluctuated significantly. In 2023, net profit was 62.41 million yuan, increasing slightly by 7.8% to 67.29 million yuan in 2024, while the first nine months of 2025 saw a net profit of 45.22 million yuan, a year-on-year increase of 1.5% [3][4]. - The gross profit margin has shown a steady upward trend, reaching 33.5% in 2023, increasing to 38.3% in 2024, and slightly declining to 37.8% in the first nine months of 2025. This improvement is attributed to economies of scale and service structure optimization [5][6]. - The net profit margin has followed a similar trend to the gross profit margin, rising from 16.8% in 2023 to 19.8% in 2024, and then decreasing to 18.5% in the first nine months of 2025 [7][8]. Revenue Composition - The company's revenue primarily comes from clinical research technical services, maintaining a share of around 85%. FSP services account for approximately 13-15%, with other revenues making up less than 2%. Notably, the share of FSP services increased by 4.8 percentage points in the first nine months of 2025, indicating a diversification in service offerings [10]. Financial Challenges - The company faces significant financial challenges, particularly regarding cash flow. In the first nine months of 2025, the net cash outflow from operating activities was 3.53 million yuan, contrasting with net inflows of 67.29 million yuan and 11.51 million yuan in 2023 and 2024, respectively. Cash and cash equivalents decreased sharply from 111 million yuan at the end of 2024 to 55.16 million yuan by September 30, 2025, a decline of 50.3% [12]. - The company has a high accounts receivable turnover days, which increased from 44 days in 2023 to 89 days in the first nine months of 2025, significantly exceeding the industry average of around 60 days. This trend indicates a weakening ability to collect receivables, increasing the risk of bad debts and funding costs [13]. Client and Supplier Concentration - The company exhibits a certain level of client concentration risk, with the top five clients contributing over 40% of revenue. In 2025, the top five clients accounted for 46% of revenue, with the largest client contributing 20.3% [14]. - Although supplier concentration data is not detailed, the accounts payable turnover days have increased from 79 days in 2023 to 130 days in the first nine months of 2025, suggesting extended payment terms to suppliers, which may affect supply chain stability [15]. Ownership and Governance - The company is controlled by Zhao Min, who directly holds 61.01% of the shares and indirectly controls an additional 17.32% through employee incentive platforms, totaling 78.33% control. This concentrated ownership may lead to governance risks due to over-reliance on the controlling shareholder for decision-making [16][17].